Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: A randomized controlled trial (SARA)

Antiviral Therapy

Volumn 17, Issue 7, 2012, Pages 1363-1373

  Gilks, Charles F ^a   Walker, A Sarah ^b   Dunn, David T ^b   Gibb, Diana M ^b   Kikaire, Ben ^c   Reid, Andrew ^d   Musana, Hellen ^e   Mambule, Ivan ^f   Kasirye, Ronnie ^c   Robertson, Val ^d   Ssali, Francis ^e   Spyer, Moira ^b   Pillay, Deenan ^g   Yirrell, David ^h   Kaleebu, Pontiano ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c MRC   (Uganda)

^d UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^e JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^f Infectious Diseases Institute   (Uganda)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; AFRICA; ARTICLE; CARDIOMYOPATHY; CD4 LYMPHOCYTE COUNT; CHRONIC DIARRHEA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CONVULSION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EAR INFECTION; FEMALE; FOLLOW UP; GASTRITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NIGHTMARE; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THRUSH; VIREMIA; VIRUS LOAD; VOMITING; WEIGHT REDUCTION;

ADULT; AFRICA; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; MUTATION; RITONAVIR; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 84870542727     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2253     Document Type: Article

References (30)

1. Gilks CF, Crowley S, Ekpini R, et al. The WHO publichealth approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
2. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. Geneva: World Health Organization 2010.
3. WHO/UNAIDS/UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. Geneva, Switzerland: WHO press 2010.
4. Mathis S, Khanlari B, Pulido F, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS ONE 2011; 6:e22003.
5. Pérez-Valero I, Arribas JR. Protease inhibitor monotherapy. Curr Opin Infect Dis 2011; 24:7-11.
6. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375:123-131.
7. Ndembi N, Goodall RL, Dunn DT, et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis 2010; 201:106-113.
8. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-163.
9. Liu TF, Shafer RW. Web resources for HIV type 1 genotypicresistance test interpretation. Clin Infect Dis 2006; 42:1608-1618.
10. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Clinical safety data management: definitions and standards for expedited reporting (E2A). (Accessed 8 October 2012.) Available from http://www.emea.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500002749.pdf
11. Division of AIDS. Table for grading severity of adult adverse experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases 1992.
12. Interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec 1990; 65:221-224.
13. Kantor R, Diero L, Delong A, et al. Misclassification of firstline antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49:454-462.
14. + T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477-484.
15. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-291.
16. Bartlett JA, Ribaudo HJ, Wallis CL et al. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS 2012; 26:1345-1354.
17. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther 2012; doi: 10.3851/IMP2443.
18. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
19. Eron J, Jr., Yeni P, Gathe J, Jr., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006; 368:476-482.
20. Delaugerre C, Flandre P, Chaix ML, et al. Protease inhibitor resistance analysis in the MONARK trial comparing firstline lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53:2934-2939.
21. Pulido F, Delgado R, Perez-Valero I, et al. Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. J Antimicrob Chemother 2008; 61:1359-1361.
22. Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. Antivir Ther 2011; 16:59-65.
23. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24:223-230.
24. Barber TJ, Harrison L, Asboe D, et al. Frequency and patterns of protease gene resistance mutations in HIVinfected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother 2012; 67:995-1000.
25. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400.
26. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS 2010; 24:1651-1655.
27. Nijhuis M, van Maarseveen NM, Lastere S, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
28. Donegan KL, Walker AS, Dunn DT, et al. The prevalence of darunavir associated mutations in HIV-1 infected children in the UK. Antivir Ther 2012; 17:599-603.
29. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. Geneva: World Health Organization 2006.
30. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.